MARKET

CBMG

CBMG

Cellular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.36
-0.64
-4.00%
After Hours: 15.36 0 0.00% 16:00 03/27 EDT
OPEN
15.50
PREV CLOSE
16.00
HIGH
15.88
LOW
15.26
VOLUME
56.24K
TURNOVER
--
52 WEEK HIGH
18.99
52 WEEK LOW
10.98
MARKET CAP
297.30M
P/E (TTM)
-5.8510
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CBMG and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBMG stock price target is 23.00 with a high estimate of 27.00 and a low estimate of 19.00.

EPS

CBMG News

More
  • Benzinga's Top Upgrades, Downgrades For March 5, 2020
  • Benzinga · 03/05 15:05
  • BTIG Research Downgrades Cellular Biomedicine Gr to Neutral
  • Benzinga · 03/05 09:48
  • Cellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/02 16:23
  • Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress
  • PR Newswire · 02/28 21:05

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About CBMG

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases.
More

Webull offers kinds of Cellular Biomedicine Group Inc stock information, including NASDAQ:CBMG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBMG stock news, and many more online research tools to help you make informed decisions.